Bradford A. Zakes stated, "The extension of the expiration dating and FDA approval of our recent requests for lot release represent a significant accomplishment for ImaRx, by allowing us to generate additional value from the continued sale of our urokinase inventory well into 2009. We remain confident that the stability profile of our urokinase inventory will enable us to achieve future expiration date extensions as we market the balance of our existing unlabeled vials of urokinase."
In January 2008 ImaRx signed a Letter of Intent with Microbix Biosystems Inc. (TSE: MBX) to manufacture and continue selling urokinase beyond the existing inventory. Closing of the transaction is dependent upon the satisfactory completion of due diligence and Microbix securing adequate financing to transfer the manufacturing process. A new supply of urokinase would allow ImaRx to continue to serve its current customers. It also would provide the opportunity to expand sales to additional vascular physicians and acute care institutions and to explore clinical development of urokinase for additional vascular indications.
In connection with the urokinase acquisition in April 2006, the Company
issued a $15.0 million non-recourse promissory note to Abbott that matures
on March 31, 2008. The outstanding balance of the note plus accrued
interest, net of funds in escrow, is $10.8 million. The Company has reached
|SOURCE ImaRx Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved